Over the past two years, UK biotech firms have accelerated their sale to US buyers, a pattern analysts link to a chronic late‑stage capital shortage. With few domestic funds willing to back costly Phase III trials, entrepreneurs view American acquisition as the quickest route to commercialisation and scale.

British venture capital pools have thinned after Brexit‑related uncertainty and a slowdown in government grant programmes, leaving promising pipelines under‑funded. Meanwhile, American pharma and biotech giants sit on deep balance sheets, ready to snap up assets that fill therapeutic gaps. This financing gap forces UK founders to accept lower valuations for speed.

Investors watch the trend closely, fearing that a steady outflow could erode the UK’s reputation as a drug‑development hub. Policy makers argue that targeted tax incentives and a revived UK Innovation Investment Fund could retain talent and keep later‑stage deals domestic. Until such measures materialise, deal flow will likely stay US‑centric.